Trials / Withdrawn
WithdrawnNCT00148993
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tumor Cell Vaccine |
Timeline
- Start date
- 1998-07-01
- Completion
- 2005-07-01
- First posted
- 2005-09-08
- Last updated
- 2011-04-08
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00148993. Inclusion in this directory is not an endorsement.